XenoPort, Inc. (XNPT) Announces Inclusion of Horizant (Gabapentin Enacarbil) in Guidelines for Long-Term Treatment of Restless Legs Syndrome/Willis-Ekbom Disease
7/23/2013 9:38:48 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today the inclusion of gabapentin enacarbil, the active ingredient in Horizant® (gabapentin enacarbil) Extended-Release Tablets, as a first-line therapy in new treatment guidelines created by the Task Force of the International Restless Legs Syndrome Study Group (IRLSSG). The manuscript, published in the current issue of Sleep Medicine, provides information for physicians determining treatment choices for restless legs syndrome/Willis-Ekbom Disease (RLS/WED) based on the long-term benefits and risks of each major class of medications. Horizant is the only non-dopamine agonist and the only alpha-2-delta ligand approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe primary restless legs syndrome in adults.
Help employers find you! Check out all the jobs and post your resume.
comments powered by